|MDACC Study No:||RTOG1102 (clinicaltrials.gov NCT No: NCT01298401)|
|Title:||A Phase I Study of Induction Ganitumab (IND #113278) and Gemcitabine, followed by Ganitumab, Capecitabine, and 3D-Conformal Radiation Therapy (3D-CRT) with Subsequent Maintenance Therapy for Locally Advanced Pancreatic Cancer|
|Principal Investigator:||Christopher H. Crane|
|Treatment Agent:||Capecitabine; GANITUMAB; Gemcitabine; Radiation|
|Study Description:||The goal of this clinical research study is to learn the highest tolerable dose |
of ganitumab that can be combined with standard chemotherapy (gemcitabine and
capecitabine) and radiation for patients with locally-advanced pancreatic
cancer. The safety of this combination will also be studied.
Ganitumab is a protein that can attach to a very specific part of a cell, which
may cause cancer cells to die.
Gemcitabine is designed to block the growth of cancer cells, which may cause
cancer cells to die.
Capecitabine is designed to interfere with the growth of cancer cells.